XML 151 R16.htm IDEA: XBRL DOCUMENT v3.19.3.a.u2
Investments
 12 Months Ended
Dec. 31, 2019
Investments, Debt and Equity Securities, Equity Method Investments and Joint Ventures [Abstract]  
Investments INVESTMENTS

The following table summarizes the measurement category, balance sheet location, and balances of our equity securities (in millions):
 
 
 
 
Year Ended
Measurement Category
 
Balance Sheet Location
 
December 31,
2019
 
December 31,
2018
Fair value method
 
Prepaid expenses and other current assets
 
$
6.6

 
$
9.4

Fair value method(1)
 
Other non-current assets
 
$
2.3

 
$
4.4

Equity method
 
Other non-current assets
 
$
17.8

 
$
15.1


(1) Measured at fair value using the Net Asset Value practical expedient.
    
The following table summarizes the expense (income) recognized in earnings of our equity securities (in millions):
 
 
 
 
Year Ended
Measurement Category
 
Income Statement Location
 
December 31,
2019
 
December 31,
2018
 
December 31,
2017
Fair value method
 
Other (income) expense, net
 
$
4.9

 
$
9.5

 
$
—

Equity method
 
Other (income) expense, net
 
$
(2.7
)
 
$
(2.7
)
 
$
(0.3
)


On January 1, 2018, as a result of the adoption of ASU 2016-01 Financial Instruments - Recognition and Measurement of Financial Assets and Liabilities ("ASU 2016-01"), we made a $1.0 million cumulative-effect adjustment to Retained earnings (accumulated deficit) net of tax that consisted of net unrealized losses on previously classified as available for sale securities from OCI.

During the year ended December 31, 2018, we increased our equity method investment in Zibo Xinhua - Perrigo Pharmaceutical Company Limited by $7.5 million.